Megan Akins, DO
Family Medicine · Kingsport, TNNPI 1669768172
Payments from drug & device makers
Across 401 payments — averaging $12.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$897
- GSK$679
- AstraZeneca$212
- Pfizer$209
- Esperion Therapeutics, Inc.$189
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$451%
- Food & beverage$4,89999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 143 | $1,495 |
| Novo Nordisk | 87 | $897 |
| GSK | 65 | $679 |
| AstraZeneca | 8 | $212 |
| Pfizer | 12 | $209 |
| Esperion Therapeutics, Inc. | 11 | $189 |
| Amgen | 9 | $131 |
| Boehringer Ingelheim | 9 | $126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $112 |
| Amarin Pharma, Inc. | 6 | $95 |
| Dexcom, Inc. | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Bayer | 4 | $68 |
| Astellas Pharma US Inc | 4 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Intuitive Surgical | 1 | $52 |
| Johnson & Johnson | 3 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Abbott | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $32 |
| UCB, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Inogen, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Novartis | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Lifescan, Inc. | 1 | $11 |
How this compares
$4,944 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $60,930 |
| RybelsusSemaglutide | 45 | $55,668 |
| JardianceEmpagliflozin | 54 | $55,011 |
| EliquisApixaban | 63 | $47,847 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $45,090 |
| XareltoRivaroxaban | 70 | $45,017 |
| TrulicityDulaglutide | 42 | $41,472 |
| LinzessLinaclotide | 33 | $37,026 |
| Xtampza ErOxycodone Myristate | 38 | $34,840 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $29,876 |
| FarxigaDapagliflozin Propanediol | 17 | $17,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,475 |
| MounjaroTirzepatide | 16 | $15,387 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,242 |
| Novolog FlexpenInsulin Aspart | 20 | $8,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $897 | $116,597104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $37 | $56,86058 claims |
| Boehringer IngelheimJardiance | $126 | $55,01154 claims |
| PfizerEliquis | $209 | $47,84763 claims |
| Johnson & JohnsonXarelto | $40 | $45,01770 claims |
| AbbVieLinzess | $1,495 | $37,02633 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $212 | $30,01340 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $679 | $24,71636 claims |
| NovartisEntresto | $14 | $7,35211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Kingsport
- Emily HubbsKingsport$2.8M
- Curtis JantziKingsport$1.3M
- Warren JonesKingsport$27K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.